Integrating Patient Language into the Brintellix strategy with Kasper Christensen (Senior Global Brand Manager for Brintellix), Johan Auning (Senior Custom Insights Manager) and Michael Adair (Global Medical Advisor)
In this episode, we're talking all about patient language in patients with MDD, exploring the way they talk about their symptoms. Host Kasper Christensen (Senior Global Brand Manager for Brintellix), speaks to expert colleagues - Johan Auning (Senior Custom Insights Manager) and Dr Michael Adair (Global Medical Advisor) - about emotional blunting in patients like Detached Debbie patients, and the opportunity this offers from a strategic perspective. Diving into the results of a recent emotional blunting study, our panel today explains how these results can help us to more effectively execute the Brintellix strategy, by bridging the gap between patient language and HCP's understanding.
We leave you with learnings from the episode that you can keep in mind when you're implementing the Brintellix strategy in your own local market.
Key Takeaways:
[0:05] Introduction
[01:38] What is emotional blunting and what was the recent study on emotional blunting?
[03:12] What did the emotional blunting study show and what is the opportunity here for Brintellix?
[05:57] How can we use patient language to link Detached Debbie to the real patient in the mind of the physician?
[09:09] Some examples of patient language used to talk about emotional blunting - 'I'm feeling numb' or 'I don't feel happy or sad'
[10:44] How can we use these learnings to help execute the Brintellix strategy?
[15:10] Key takeaways: All the insights from the research are available to you in the Brintellix Patient-Physician Dialogue Playbook; the playbook contains guidance on what language resonates best when describing the four symptoms of Detached Debbie; emotional blunting is particularly difficult to unpack, so it's especially important to digest this guidance on how best to encourage physicians to make the connection to Brintellix as a first choice treatment.
[17:41] END
Resources:
